Role of the melatonin system in the control of sleep: Therapeutic implications

CNS Drugs

Volumn 21, Issue 12, 2007, Pages 995-1018

  Pandi Perumal, Seithikurippu R ^a   Srinivasan, Venkatramanujan ^b   Spence, D Warren ^c   Cardinali, Daniel P ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Agomelatine, general; Circadian rhythm sleep disorders; Insomnia; Melatonin receptor agonists, general; Melatonin, general; Ramelteon, general; Sleep disorders

Indexed keywords

ACETYLSEROTONIN METHYLTRANSFERASE; AGOMELATINE; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUVOXAMINE; MELATONIN; MELATONIN RECEPTOR; NORADRENALIN; RAMELTEON; SEROTONIN;

ABSENCE OF SIDE EFFECTS; ADVANCED SLEEP PHASE SYNDROME; ALZHEIMER DISEASE; BIOSYNTHESIS; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL; CONFUSION; DELAYED SLEEP PHASE SYNDROME; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FATIGUE; HEADACHE; HORMONE METABOLISM; HUMAN; HYPNOSIS; HYPOTHALAMUS; INSOMNIA; JET LAG; MACACA; MUSCLE CRAMP; NAUSEA; NON 24 HOUR SLEEP WAKE SYNDROME; NONHUMAN; PINEAL BODY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT STRAIN; RECEPTOR DENSITY; REM SLEEP; RETINA GANGLION CELL; REVIEW; SHIFT WORKER; SLEEP; SLEEP DISORDER; SLEEP WAKING CYCLE; SMITH MAGENIS SYNDROME; SUPRACHIASMATIC NUCLEUS; SUSTAINED DRUG RELEASE; VOMITING;

ANIMALS; HUMANS; MELATONIN; RECEPTORS, MELATONIN; SLEEP; SLEEP DISORDERS;

EID: 36248949004     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721120-00004     Document Type: Review

References (230)

1. Lerner AB, Case JD, Takahashi Y, et al. Isolation of melatonin, a pineal factor that lightens melanocytes [letter]. J Am Chem Soc 1958; 80: 2587
2. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, et al. Melatonin: nature's most versatile biological signal? FEBS J 2006; 273 (13): 2813-38
3. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9 (1): 11-24
4. Wurtman RJ. The pineal as a neuroendocrine transducer. Hosp Pract 1980; 15 (1): 82-86, 91-92
5. Zisapel N. Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. CNS Drugs 2001; 15 (4): 311-28
6. Liu C, Weaver DR, Jin X, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997; 19 (1): 91-102
7. 1b melatonin receptor. Mol Cell Biol 2003; 23 (3): 1054-60
8. Dijk DJ, Cajochen C. Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. J Biol Rhythms 1997; 12 (6): 627-35
9. Lavie P. Melatonin: role in gating nocturnal rise in sleep propensity. J Biol Rhythms 1997; 12 (6): 657-65
10. Wehr TA. Photoperiodism in humans and other primates: evidence and implications. J Biol Rhythms 2001; 16 (4): 348-64
11. Cajochen C, Krauchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 2003; 15 (4): 432-7
12. Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 2004; 25 (3-4): 177-95
13. Zhdanova IV, Tucci V. Melatonin, circadian rhythms, and sleep. Curr Treat Options Neurol 2003; 5 (3): 225-9
14. Baskett JJ, Wood PC, Broad JB, et al. Melatonin in older people with age-related sleep maintenance problems: a comparison with age matched normal sleepers. Sleep 2001; 24 (4): 418-24
15. Lushington K, Dawson D, Kennaway DJ, et al. The relationship between 6-sulphatoxymelatonin and polysomnographic sleep in good sleeping controls and wake maintenance insomniacs, aged 55-80 years. J Sleep Res 1999; 8 (1): 57-64
16. Haimov I, Laudon M, Zisapel N, et al. Sleep disorders and melatonin rhythms in elderly people [letter]. BMJ 1994; 309 (6948): 167
17. Hajak G, Rodenbeck A, Adler L, et al. Nocturnal melatonin secretion and sleep after doxepin administration in chronic reacprimary insomnia. Pharmacopsychiatry 1996; 29 (5): 187-92
18. Rodenbeck A, Huether G, Hajak G. Sleep disorders and aging: understanding the causes. In: Touitou Y, editor. Biological clocks, mechanisms and application. Amsterdam: Elsevier, 1998: 329-32
19. Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004; 116 (2): 91-5
20. MacFarlane J, Cleghorn J, Brown G. Melatonin and core temperature rhythm in chronic insomnia. Adv Biosci 1984; 53: 303-6
21. Kripke DF, Elliot JA, Youngstedt SD, et al. Melatonin: marvel or marker? Ann Med 1998; 30 (1): 81-7
22. Pandi-Perumal SR, Zisapel N, Srinivasan V, et al. Melatonin and sleep in aging population. Exp Gerontol 2005; 40 (12): 911-25
23. Zhdanova IV, Wurtman RJ, Regan MM, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001; 86 (10): 4727-30
24. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev 2005; 9 (1): 25-39
25. Srinivasan V, Smits G, Kayumov L, et al. Melatonin in circadian rhythm sleep disorders. In: Cardinali DP, Pandi-Perumal SR, editors. Neuroendocrine correlates of sleep/wakefulness. New York: Springer, 2006: 269-94
26. Cardinali DP, Furio AM, Reyes MP, et al. The use of chronobiotics in the resynchronization of the sleep-wake cycle. Cancer Causes Control 2006; 17 (4): 601-9
27. Cardinali DP, Rosner JM. Metabolism of serotonin by the rat retina "in vitro". J Neurochem 1971; 18: 1769-70
28. Tosini G, Menaker M. The clock in the mouse retina: melatonin synthesis and photoreceptor degeneration. Brain Res 1998; 789 (2): 221-8
29. Raikhlin NT, Kvetnoy IM, Tolkachev VN. Melatonin may be synthesised in enterochromaffin cells. Nature 1975; 255 (5506): 344-5
30. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002; 47 (10): 2336-48
31. Slominski A, Fischer TW, Zmijewski MA, et al. On the role of melatonin in skin physiology and pathology. Endocrine 2005; 27 (2): 137-48
32. Carrillo-Vico A, Calvo JR, Abreu P, et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004; 18 (3): 537-9
33. Champier J, Claustrat B, Besancon R, et al. Evidence for tryptophan hydroxylase and hydroxy-indole-O-methyl-transferase mRNAs in human blood platelets. Life Sci 1997; 60 (24): 2191-7
34. Conti A, Conconi S, Hertens E, et al. Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 2000; 28 (4): 193-202
35. Tricoire H, Moller M, Chemineau P, et al. Origin of cerebrospinal fluid melatonin and possible function in the integration of photoperiod. Reprod Suppl 2003; 61: 311-21
36. Cardinali DP, Pévet P. Basic aspects of melatonin action. Sleep Med Rev 1998; 2 (3): 175-90
37. Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 2003; 17 (2): 273-85
38. Touitou Y. Human aging and melatonin: clinical relevance. Exp Gerontol 2001; 36 (7): 1083-100
39. Hirata F, Hayaishi O, Tokuyama T, et al. In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem 1974; 249 (4): 1311-3
40. Tan DX, Manchester LC, Terron MP, et al. One molecule, many derivatives: a never-ending interaction of melatonin with reative oxygen and nitrogen species? J Pineal Res 2007; 42 (1): 28-42
41. 7 meatonin. Biopharm Drug Dispos 2000; 21 (1): 15-22
42. Hartter S, Grozinger M, Weigmann H, et al. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 2000; 67 (1): 1-6
43. Hartter S, Nordmark A, Rose DM, et al. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol 2003; 56 (6): 679-82
44. Morin LP, Allen CN. The circadian visual system, 2005. Brain Res Brain Res Rev 2006; 51 (1): 1-60
45. Hannibal J. Roles of PACAP-containing retinal ganglion cells in circadian timing. Int Rev Cytol 2006; 251: 1-39
46. Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science 2002; 295 (5557): 1070-3
47. Brainard GC, Hanifin JP, Greeson JM, et al. Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci 2001; 21 (16): 6405-12
48. Saper CB, Lu J, Chou TC, et al. The hypothalamic integrator for circadian rhythms. Trends Neurosci 2005; 28 (3): 152-7
49. Moore RY. Neural control of the pineal gland. Behav Brain Res 1996; 73 (1-2): 125-30
50. Klein DC, Weller JL, Moore RY. Melatonin metabolism: neural regulation of pineal serotonin: acetyl coenzyme A N-acetyl-transferase activity. Proc Natl Acad Sci U S A 1971; 68 (12): 3107-10
51. Vacas MI, Lowenstein P, Cardinali DP. Dihydroergocryptine binding sites in bovine and rat pineal glands. J Auton Nerv Syst 1980; 2: 305-13
52. 2 activity. J Biol Chem 1987; 262 (24): 11764-70
53. Krause DN, Dubocovich ML. Regulatory sites in the melatonin system of mammals. Trends Neurosci 1990; 13 (11): 464-70
54. 2+, pCREB, and ICER. Naturwissenschaften 1996; 83 (12): 535-43
55. Klein DC, Schaad NL, Namboordiri MA, et al. Regulation of pineal serotonin N-acetyltransferase activity. Biochem Soc Trans 1992; 20 (2): 299-304
56. Ribelayga C, Pévet P, Simonneaux V. HIOMT drives the photoperiodic changes in the amplitude of the melatonin peak of the Siberian hamster. Am J Physiol Regul Integr Comp Physiol 2000; 278 (5): R1339-45
57. Ceinos RM, Chansard M, Revel F, et al. Analysis of adrenergic regulation of melatonin synthesis in Siberian hamster pineal emphasizes the role of HIOMT. Neurosignals 2004; 13 (6): 308-17
58. Liu T, Borjigin J. N-acetyltransferase is not the rate-limiting enzyme of melatonin synthesis at night. J Pineal Res 2005; 39 (1): 91-6
59. 1b melatonin receptor. Proc Natl Acad Sci U S A 1995; 92 (19): 8734-8
60. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13 (5): 1177-85
61. 2 melatonin receptors in mammals. Endocrine 2005; 27 (2): 101-10
62. 1a melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport 1996; 8 (1): 109-12
63. McArthur AJ, Hunt AE, Gillette MU. Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: activation of protein kinase C at dusk and dawn. Endocrinology 1997; 138 (2): 627-34
64. 3 as the quinone reductase 2. J Biol Chem 2000; 275 (40): 31311-7
65. 1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Neurobiol Aging 2006; 28 (8): 1239-47
66. Borbely AA. A two process model of sleep regulation. Hum Neurobiol 1982; 1 (3): 195-204
67. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005; 437 (7063): 1257-63
68. Pace-Schott EF, Hobson JA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nature Neurosci Rev 2002; 3: 591-605
69. Dijk DJ, von Schantz M. Timing and consolidation of human sleep, wakefulness, and performance by a symphony of oscillators. J Biol Rhythms 2005; 20 (4): 279-90
70. Dijk DJ, Lockley SW. Integration of human sleep-wake regulation tion and circadian rhythmicity. J Appl Physiol 2002; 92 (2): 852-62
71. Zee PC, Manthena P. The brain's master circadian clock: implications and opportunities for therapy of sleep disorders. Sleep Med Rev 2007; 11 (1): 59-70
72. Lynch HJ, Wurtman RJ, Moskowitz MA, et al. Daily rhythm in human urinary melatonin. Science 1975; 187 (4172): 169-71
73. Pandi-Perumal SR, Smits M, Spence W, et al. Dim light melatonin onset (DLMO): a tool for the analysis of circadian phase in human sleep and chronobiological disorders. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1-11
74. Gorfine T, Assaf Y, Goshen-Gottstein Y, et al. Sleep-anticipating effects of melatonin in the human brain. Neuroimage 2006; 31 (1): 410-8
75. Tzischinsky O, Shlitner A, Lavie P. The association between the nocturnal sleep gate and nocturnal onset of urinary 6-sulfatoxymelatonin. J Biol Rhythms 1993; 8 (3): 199-209
76. Zhdanova IV, Wurtman RJ, Morabito C, et al. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996; 19 (5): 423-31
77. Brismar K, Mogensen L, Wetterberg L. Depressed melatonin secretion in patients with nightmares due to beta-adrenoceptor blocking drugs. Acta Med Scand 1987; 221 (2): 155-8
78. van den Heuvel CJ, Reid KJ, Dawson D. Effect of atenolol on nocturnal sleep and temperature in young men: reversal by pharmacological doses of melatonin. Physiol Behav 1997; 61 (6): 795-802
79. Hartter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol 2001; 21 (2): 167-74
80. Haimov I, Lavie P. Melatonin: a chronobiotic and soporific hormone. Arch Gerontol Geriatr 1997; 24 (2): 167-73
81. Strogatz SH, Kronauer RE, Czeisler CA. Circadian regulation dominates homeostatic control of sleep length and prior wake length in humans. Sleep 1986; 9 (2): 353-64
82. Lavie P. Ultrashort sleep-waking schedule: III. 'Gates' and 'forbidden zones' for sleep. Electroencephalogr Clin Neurolatonin physiol 1986; 63 (5): 414-25
83. Buysse DJ, Nofzinger EA, Germain A, et al. Regional brain glucose metabolism during morning and evening wakefulness in humans: preliminary findings. Sleep 2004; 27 (7): 1245-54
84. Long MA, Jutras MJ, Connors BW, et al. Electrical synapses coordinate activity in the suprachiasmatic nucleus. Nat Neurosci 2005; 8 (1): 61-6
85. Birkeland AJ. Plasma melatonin levels and nocturnal transitions between sleep and wakefulness. Neuroendocrinology 1982; 34 (2): 126-31
86. Sack RL, Hughes RJ, Edgar DM, et al. Sleep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms? Sleep 1997; 20 (10): 908-15
87. 2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol 2001; 280 (1): C110-8
88. Zhdanova IV, Cantor ML, Leclair OU, et al. Behavioral effects of melatonin treatment in non-human primates. Sleep Res Online 1998; 1 (3): 114-8
89. Zhdanova IV, Geiger DA, Schwagerl AL, et al. Melatonin promotes sleep in three species of diurnal nonhuman primates. Physiol Behav 2002; 75 (4): 523-9
90. Mintz EM, Phillips NH, Berger RJ. Daytime melatonin infusions induce sleep in pigeons without altering subsequent amounts of nocturnal sleep. Neurosci Lett 1998; 258 (2): 61-4
91. Murakami N, Kawano T, Nakahara K, et al. Effect of melatonin on circadian rhythm, locomotor activity and body temperature in the intact house sparrow, Japanese quail and owl. Brain Res 2001; 889 (1-2): 220-4
92. Zhdanova IV, Wang SY, Leclair OU, et al. Melatonin promotes sleep-like state in zebrafish. Brain Res 2001; 903 (1-2): 263-8
93. Zhdanova IV. Melatonin as a hypnotic: pro. Sleep Med Rev 2005; 9 (1): 51-65
94. Lerner AB, Case MD. Melatonin. Fed Proc 1960; 19: 590-2
95. Anton-Tay F, Diaz JL, Fernandez-Guardiola A. On the effect of melatonin upon human brain: its possible therapeutic implications. Life Sci I 1971; 10 (15): 841-50
96. Cramer H, Rudolph J, Consbruch U, et al. On the effects of melatonin on sleep and behavior in man. Adv Biochem Psychopharmacol 1974; 11: 187-91
97. Vollrath L, Semm P, Gammel G. Sleep induction by intranasal administration of melatonin. Adv Biosci 1981; 29: 327-9
98. Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (Berl) 1990; 100 (2): 222-6
99. Dollins AB, Lynch HJ, Wurtman RJ, et al. Effect of pharmacological daytime doses of melatonin on human mood and performance. Psychopharmacology (Berl) 1993; 112 (4): 490-6
100. Nave R, Peled R, Lavie P. Melatonin improves evening napping. Eur J Pharmacol 1995; 275 (2): 213-6
101. Dollins AB, Zhdanova IV, Wurtman RJ, et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A 1994; 91 (5): 1824-8
102. Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995; 57 (5): 552-8
103. Stone BM, Turner C, Mills SL, et al. Hypnotic activity of melatonin. Sleep 2000; 23 (5): 663-9
104. Tzischinsky O, Lavie P. Melatonin possesses time-dependent hypnotic effects. Sleep 1994; 17 (7): 638-45
105. Lewy AJ. Melatonin as a marker and phase-resetter of circadian rhythms in humans. Adv Exp Med Biol 1999; 460: 425-34
106. Rajaratnam SM, Middleton B, Stone BM, et al. Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol 2004; 561 (Pt 1): 339-51
107. Lockley S, Tabandeh H, Skene D, et al. Day-time naps and melatonin in blind people [letter]. Lancet 1995; 346 (8988): 1491
108. Lockley SW, Skene DJ, James K, et al. Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol 2000; 164 (1): R1-6
109. Sack RL, Brandes RW, Kendall AR, et al. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med 2000; 343 (15): 1070-7
110. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9 (1): 41-50
111. Wyatt JK, Dijk DJ, Ritz-de Cecco A, et al. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep 2006; 29 (5): 609-18
112. Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders: a meta-analysis. J Gen Intern Med 2005; 20 (12): 1151-8
113. Hughes RJ, Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep 1997; 20 (2): 124-31
114. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep 1998; 21 (1): 52-68
115. 2 melatonin receptors to cyclic AMP and phosphoinositide signal transduction cascades and their regulation following melatonin exposure. Biochem Pharmacol 2002; 63 (4): 587-95
116. 1 melatonin receptor prevents melatonin-induced receptor desensitization. Life Sci 2004; 75 (22): 2703-15
117. Ying SW, Rusak B, Mocaer E. Chronic exposure to melatonin receptor agonists does not alter their effects on suprachiasmatic nucleus neurons. Eur J Pharmacol 1998; 342 (1): 29-37
118. 2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J 2004; 18 (14): 1646-56
119. 1 melatonin receptors expressed in mammalian cells. Biochem Pharmacol 2004; 67 (11): 2023-30
120. 1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. J Pineal Res 2000; 28 (3): 185-92
121. Jarzynka MJ, Passey DK, Ignatius PF, et al. Modulation of melatonin receptors and G-protein function by microtubules. J Pineal Res 2006; 41 (4): 324-36
122. 2 receptor agonist. Neuropharmacology 2005; 48 (2): 301-10
123. Wurtman R. Ramelteon: a novel treatment for the treatment of insomnia. Expert Rev Neurother 2006; 6 (7): 957-64
124. 2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006; 46 (2): 140-8
125. Cagnacci A, Elliott JA, Yen SS. Melatonin: a major regulator of the circadian rhythm of core temperature in humans. J Clin Endocrinol Metab 1992; 75 (2): 447-52
126. Dawson D, Encel N. Melatonin and sleep in humans. J Pineal Res 1993; 15 (1): 1-12
127. Krauchi K, Cajochen C, Pache M, et al. Thermoregulatory effects of melatonin in relation to sleepiness. Chronobiol Int 2006; 23 (1-2): 475-84
128. Summers MO, Crisostomo MI, Stepanski EJ. Recent develoption ments in the classification, evaluation, and treatment of insomnia. Chest 2006; 130 (1): 276-86
129. Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 2006; 21 Suppl. 1: S25-9
130. Cricco M, Simonsick EM, Foley DJ. The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc 2001; 49 (9): 1185-9
131. Manabe K, Matsui T, Yamaya M, et al. Sleep patterns and mortality among elderly patients in a geriatric hospital. Gerontology 2000; 46 (6): 318-22
132. Kamel NS, Gammack JK. Insomnia in the elderly: cause, approach, and treatment. Am J Med 2006; 119 (6): 463-9
133. Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch Gerontol Geriatr 1997; 24 (2): 223-31
134. Haimov I, Lavie P. Potential of melatonin replacement therapy in older patients with sleep disorders. Drugs Aging 1995; 7 (2): 75-8
135. Monti JM, Alvarino F, Cardinali DP, et al. Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Arch Gerontol Geriatr 1999; 28: 85-98
136. 2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005; 28 (3): 303-7
137. Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006; 7 (1): 17-24
138. Pandi-Perumal SR, Srinivasan V, Cardinali DP, et al. Could agomelatine be the ideal antidepressant? Expert Rev Neurother 2006; 6 (11): 1595-608
139. Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006; 20 (12): 981-92
140. James SP, Sack DA, Rosenthal NE, et al. Melatonin administration in insomnia. Neuropsychopharmacology 1990; 3 (1): 19-23
141. Haimov I, Lavie P, Laudon M, et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995; 18 (7): 598-603
142. Ellis CM, Lemmens G, Parkes JD. Melatonin and insomnia. J Sleep Res 1996; 5 (1): 61-5
143. Shamir E, Rotenberg VS, Laudon M, et al. First-night effect of melatonin treatment in patients with chronic schizophrenia. J Clin Psychopharmacol 2000; 20 (6): 691-4
144. Andrade C, Srihari BS, Reddy KP, et al. Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry 2001; 62 (1): 41-5
145. Smits MG, Nagtegaal EE, van der Heijden J, et al. Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial. J Child Neurol 2001; 16 (2): 86-92
146. Smits MG, van Stel HF, van der Heijden K, et al. Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2003; 42 (11): 1286-93
147. Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003; 26 (7): 893-901
148. Asayama K, Yamadera H, Ito T, et al. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch 2003; 70 (4): 334-41
149. Ivanenko A, Crabtree VM, Tauman R, et al. Melatonin in children and adolescents with insomnia: a retrospective study. Clin Pediatr (Phila) 2003; 42 (1): 51-8
150. Campos FL, Silva-Junior FP, de Bruin VM, et al. Melatonin improves sleep in asthma: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2004; 170 (9): 947-51
151. Dowling GA, Mastick J, Colling E, et al. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 2005; 6 (5): 459-66
152. Weiss M, Wasdell M, Bomben M, et al. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry 2006; 45 (5): 512-9
153. Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004; 5 (6): 523-32
154. Hirai K, Kita M, Ohta H, et al. Ramelteon (TAK-375) accelerates re-entrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 2005; 20 (1): 27-37
155. Cajochen C. TAK-375 Takeda. Curr Opin Investig Drugs 2005; 6 (1): 114-21
156. Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006; 7 (4): 312-8
157. Bellon A. Searching for new options for treating insomnia: are melatonin and ramelteon beneficial? J Psychiatr Pract 2006; 12 (4): 229-43
158. Stevenson S, Bryson S, Amayke D, et al. Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects [abstract]. Clin Pharmacol Ther 2004; 75: 22
159. Rozerem™ (prescribing information). Lincolnshire (IL): Takeda Pharmaceuticals America, Inc., 2005, rev. 2006 Apr
160. Ying SW, Rusak B, Delagrange P, et al. Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. Eur J Pharmacol 1996; 296 (1): 33-42
161. 2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17 (5): 239-47
162. 2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005; 60 (5): 441-60
163. Delagrange P, Boutin JA. Therapeutic potential of melatonin ligands. Chronobiol Int 2006; 23 (1-2): 413-8
164. Leproult R, Van Onderbergen A, L'hermite-Baleriaux M, et al. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf) 2005; 63 (3): 298-304
165. Quera-Salva MA, Vanier B, Chapotot F. Effect of agomelatine on the sleep EEG in patients with major depressive disorders (MDD) [abstract]. Eur Neuropsychopharmacol 2005; 15 Suppl. 3: S435
166. Dubocovich ML. Agomelatine targets a range of major depressive disorder symptoms. Curr Opin Investig Drugs 2006; 7 (7): 670-80
167. Liu RY, Zhou JN, van Heerikhuize J, et al. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 1999; 84: 323-7
168. McCurry SM, Reynolds CF, Ancoli-Israel S, et al. Treatment of sleep disturbance in Alzheimer's disease. Sleep Med Rev 2000; 4 (6): 603-28
169. Wu YH, Feenstra MG, Zhou JN, et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003; 88 (12): 5898-906
170. Mishima K, Tozawa T, Satoh K, et al. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol Psychiatry 1999; 45 (4): 417-21
171. Fainstein I, Bonetto A, Brusco LI, et al. Effects of melatonin in elderly patients with sleep disturbance: a pilot study. Curr Ther Res 1997; 58: 990-1000
172. Jean-Louis G, von Gizycki H, Zizi F. Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J Pineal Res 1998; 25 (3): 177-83
173. Brusco LI, Marquez M, Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol Lett 1998; 19: 111-5
174. Cardinali DP, Brusco LI, Liberczuk C, et al. The use of melatonin in Alzheimer's disease. Neuroendocrinol Lett 2002; 23 Suppl. 1: 20-3
175. Mahlberg R, Kunz D, Sutej I, et al. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J Clin Psychopharmacol 2004; 24 (4): 456-9
176. Jan JE, Freeman RD. Melatonin therapy for circadian rhythm sleep disorders in children with multiple disabilities: what have we learned in the last decade? Dev Med Child Neurol 2004; 46 (11): 776-82
177. Van der Heijden KB, Smits MG, Van Someren EJ, et al. Prediction of melatonin efficacy by pretreatment dim light melatonin onset in children with idiopathic chronic sleep onset insomnia. J Sleep Res 2005; 14 (2): 187-94
178. Jan JE, Espezel H, Appleton RE. The treatment of sleep disorders with melatonin. Dev Med Child Neurol 1994; 36 (2): 97-107
179. 1- adrenergic antagonists and melatonin reset the clock and restore sleep in a circadian disorder, Smith-Magenis syndrome. J Med Genet 2003; 40 (1): 74-8
180. De Leersnyder H. Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment. Trends Endocrinol Metab 2006; 17 (7): 291-8
181. Asato MR, Hardan AY. Neuropsychiatric problems in tuberous sclerosis complex. J Child Neurol 2004; 19 (4): 241-9
182. O'Callaghan FJ, Clarke AA, Hancock E, et al. Use of melatonin to treat sleep disorders in tuberous sclerosis. Dev Med Child Neurol 1999; 41 (2): 123-6
183. Tordjman S, Anderson GM, Pichard N, et al. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biol Psychiatry 2005; 57 (2): 134-8
184. Giannotti F, Cortesi F, Cerquiglini A, et al. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord 2006; 36 (6): 741-52
185. Jan MM. Melatonin for the treatment of handicapped children with severe sleep disorders. Pediatr Neurol 2000; 23 (3): 229-32
186. Wassmer E, Whitehouse WP. Melatonin and sleep in children with neurodevelopmental disabilities and sleep disorders. Current Paediatrics 2006; 16 (2): 132-8
187. Weitzman ED, Czeisler CA, Coleman RM, et al. Delayed sleep phase syndrome: a chronobiological disorder with sleep-onset insomnia. Arch Gen Psychiatry 1981; 38 (7): 737-46
188. Regestein QR, Monk TH. Delayed sleep phase syndrome: review of its clinical aspects. Am J Psychiatry 1995; 152 (4): 602-8
189. Wyatt JK, Stepanski EJ, Kirkby J. Circadian phase in delayed sleep phase syndrome: predictors and temporal stability across multiple assessments. Sleep 2006; 29 (8): 1075-80
190. Oren DA, Turner EH, Wehr TA. Abnormal circadian rhythms of plasma melatonin and body temperature in the delayed sleep phase syndrome [letter]. J Neurol Neurosurg Psychiatry 1995; 58 (3): 379
191. Hohjoh H, Takasu M, Shishikura K, et al. Significant association of the arylalkylamine N-acetyltransferase (AA-NAT) gene with delayed sleep phase syndrome. Neurogenetics 2003; 4 (3): 151-3
192. Dahlitz M, Alvarez B, Vignau J, et al. Delayed sleep phase syndrome response to melatonin. Lancet 1991; 337 (8750): 1121-4
193. Lewy AJ, Ahmed S, Jackson JM, et al. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992; 9 (5): 380-92
194. Oldani A, Ferini-Strambi L, Zucconi M, et al. Melatonin and delayed sleep phase syndrome: ambulatory polygraphic evaluation. Neuroreport 1994; 6 (1): 132-4
195. Nagtegaal E, Peeters T, Swart W, et al. Correlation between concentrations of melatonin in saliva and serum in patients with delayed sleep phase syndrome. Ther Drug Monit 1998; 20 (2): 181-3
196. Kayumov L, Brown G, Jindal R, et al. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom Med 2001; 63 (1): 40-8
197. Mundey K, Benloucif S, Harsanyi K, et al. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep 2005; 28 (10): 1271-8
198. Reid KJ, Chang AM, Dubocovich ML, et al. Familial advanced sleep phase syndrome. Arch Neurol 2001; 58 (7): 1089-94
199. Jones CR, Campbell SS, Zone SE, et al. Familial advanced sleep-phase syndrome: a short-period circadian rhythm variant in humans. Nat Med 1999; 5 (9): 1062-5
200. Satoh K, Mishima K, Inoue Y, et al. Two pedigrees of familial advanced sleep phase syndrome in Japan. Sleep 2003; 26 (4): 416-7
201. 2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science 2001; 291 (5506): 1040-3
202. Czeisler CA, Kronauer RE, Mooney JJ, et al. Biologic rhythm disorders, depression, and phototherapy: a new hypothesis. Psychiatr Clin North Am 1987; 10 (4): 687-709
203. Lockley SW, Skene DJ, Tabandeh H, et al. Relationship between napping and melatonin in the blind. J Biol Rhythms 1997; 12 (1): 16-25
204. Shibui K, Okawa M, Uchiyama M, et al. Continuous measurement of temperature in non-24 hour sleep-wake syndrome. Psychiatry Clin Neurosci 1998; 52 (2): 236-7
205. McArthur AJ, Lewy AJ, Sack RL. Non-24-hour sleep-wake syndrome in a sighted man: circadian rhythm studies and efficacy of melatonin treatment. Sleep 1996; 19 (7): 544-53
206. Palm L, Blennow G, Wetterberg L. Long-term melatonin treatment in blind children and young adults with circadian sleep-wake disturbances. Dev Med Child Neurol 1997; 39 (5): 319-25
207. Folkard S, Arendt J, Aldhous M, et al. Melatonin stabilises sleep onset time in a blind man without entrainment of cortisol or temperature rhythms. Neurosci Lett 1990; 113 (2): 193-8
208. Arendt J, Marks V. Physiological changes underlying jet lag. Br Med J (Clin Res Ed) 1982; 284 (6310): 144-6
209. Cardinali DP, Brusco LI, Lloret SP, et al. Melatonin in sleep disorders and jet-lag. Neuroendocrinol Lett 2002; 23 Suppl. 1: 9-13
210. Oxenkrug GF, Requintina PJ. Melatonin and jet lag syndrome: experimental model and clinical implications. CNS Spectr 2003; 8 (2): 139-48
211. Cardinali DP, Bortman GP, Liotta G, et al. A multifactorial approach employing melatonin to accelerate resynchronization of sleep-wake cycle after a 12 time-zone westerly transmeridian flight in elite soccer athletes. J Pineal Res 2002; 32 (1): 41-6
212. Suhner A, Schlagenhauf P, Johnson R, et al. Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag. Chronobiol Int 1998; 15 (6): 655-66
213. Burch JB, Yost MG, Johnson W, et al. Melatonin, sleep, and shift work adaptation. J Occup Environ Med 2005; 47 (9): 893-901
214. Drake CL, Roehrs T, Richardson G, et al. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep 2004; 27 (8): 1453-62
215. Akerstedt T. Shift work and sleep disorders. Sleep 2005; 28 (1): 9-11
216. Van Reeth O. Sleep and circadian disturbances in shift work: strategies for their management. Horm Res 1998; 49 (3-4): 158-62
217. Sack RL, Blood ML, Lewy AJ. Melatonin rhythms in night shift workers. Sleep 1992; 15 (5): 434-41
218. Roden M, Koller M, Pirich K, et al. The circadian melatonin and cortisol secretion pattern in permanent night shift workers. Am J Physiol 1993; 265 (1 Pt 2): R261-7
219. Weibel L, Spiegel K, Gronfier C, et al. Twenty-four-hour melatonin and core body temperature rhythms: their adaptation in night workers. Am J Physiol 1997; 272 (3 Pt 2): R948-54
220. Folkard S, Arendt J, Clark M. Can melatonin improve shift workers' tolerance of the night shift? Some preliminary findings. Chronobiol Int 1993; 10 (5): 315-20
221. Jorgensen KM, Witting MD. Does exogenous melatonin improve day sleep or night alertness in emergency physicians working night shifts? Ann Emerg Med 1998; 31 (6): 699-704
222. Burgess HJ, Sharkey KM, Eastman CI. Bright light, dark and melatonin can promote circadian adaptation in night shift workers. Sleep Med Rev 2002; 6 (5): 407-20
223. Quera-Salva MA, Guilleminault C, Claustrat B, et al. Rapid shift in peak melatonin secretion associated with improved performance in short shift work schedule. Sleep 1997; 20 (12): 1145-50
224. Cavallo A, Ris MD, Succop P, et al. Melatonin treatment of pediatric residents for adaptation to night shift work. Ambul Pediatr 2005; 5 (3): 172-7
225. Arendt J. Safety of melatonin in long-term use (?). J Biol Rhythms 1997; 12 (6): 673-81
226. Guardiola-Lemaitre B. Toxicology of melatonin. J Biol Rhythms 1997; 12 (6): 697-706
227. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2002; (2): CD001520
228. Jacob S, Poeggeler B, Weishaupt JH, et al. Melatonin as a candidate compound for neuroprotection in amyotrophic laterings. al sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients. J Pineal Res 2002; 33 (3): 186-7
229. Weishaupt JH, Bartels C, Polking E, et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006; 41 (4): 313-23
230. Maestroni GJM, Cardinali DP, Esquifino AI, et al. Does melatonin play a disease-promoting role in rheumatoid arthritis? J Neuroimmunol 2004; 158: 106-11